Overlooked....., page-5

First 5 Last

Share
Profile

Follow
Sparkz918

240 Posts.

9

27/02/18

22:54

Post #: 31396939
Share

Originally posted by Reillyblue ↑

Most recent posts on this forum have focussed on the Korean Deal and I believe we have become myopic in our views of the company.
The occasional post, rightly, points out that we have many "irons in the fire." GIMP, Cannepil, Derma range, Australian License etc. There is one that I think we may have overlooked.
In the half yearly the company reported on the relationship with RMIT and in particular the research into how medicinal marijuana can impact cancer, causes and symptoms.
There are a few words that are bobbing around the investment world at the moment that make people sit up and take notice. Lithium, Microgrids, Infant formula, Blockchain, MM and cancer (relief or cure).
I have not seen too many posts on this topic, hence I think we may be dismissing the value of the RMIT relationship. Just imagine the impact on our share price if we had an announcement with "MM" and "Cancer" in the title followed by the first line "MGC and RMIT are pleased to announce that....."

Expand

I completely agree.

Seriously, if it's not that ASX query letter made our sp droped to 7.8c at one point, our SP should be sitting at least same as ZLD at around 14c

AIMO DYOR

MXC Price at posting: 9.7¢ Sentiment: None Disclosure: Not Held
Upvote

0 Great analysis

Reply

Top Stories

D3E

D3 Energy detects gas in South African helium hunt well

SEN

Senetas experiences stronger cash flow as revenue rises, flags FY27 sales pipeline

NVA

Nova Minerals achieves key milestone on path to Alaskan antimony production

4DX

4DMedical posts FY26 revenue growth as commercial deployment ramps up

HotCopper Highlights Week 35: X2M, AnteoTech and Brighstar dominate forum chatter

IMR

Imricor Med and Philips launch commercial iMR lab solution

AS2

Capital Compass: Askari Metals advances Ethiopia strategy as permitting remains key focus

TGN

Tungsten has soared +700% YTD, the US is curbing its exports, and this ASX stock is targeting production in Q1CY27

MEM

Memphasys receives early Thai FDA Felix approval

CVL

Civmec earnings: Profit climbs as $1.4b order book backs FY27 growth

First 5 Last

Add to My Watchlist

What is My Watchlist?

A personalised tool to help users track selected stocks. Delivering real-time notifications on price updates, announcements, and performance stats on each to help make informed investment decisions.

Overlooked....., page-5

Top Stories

D3 Energy detects gas in South African helium hunt well

Senetas experiences stronger cash flow as revenue rises, flags FY27 sales pipeline

Nova Minerals achieves key milestone on path to Alaskan antimony production

4DMedical posts FY26 revenue growth as commercial deployment ramps up

HotCopper Highlights Week 35: X2M, AnteoTech and Brighstar dominate forum chatter

Imricor Med and Philips launch commercial iMR lab solution

Capital Compass: Askari Metals advances Ethiopia strategy as permitting remains key focus

Tungsten has soared +700% YTD, the US is curbing its exports, and this ASX stock is targeting production in Q1CY27

Memphasys receives early Thai FDA Felix approval

Civmec earnings: Profit climbs as $1.4b order book backs FY27 growth

Featured News